Lindus Health RAISES $55M in SERIES B FUNDING.
READ MORE
Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialized healthcare brands, have today announced the completion of enrollment of a trial to assess the effectiveness of their personalized dermatology telemedicine platform Facet.
The novel telehealth platform offers treatment to patients with various skin conditions, such as atopic dermatitis (eczema), through asynchronous evidence-based consultation, patient-reported monitoring and provider messaging. This involves using before and after photos as well as patient reports to monitor progress.
The announcement follows a study by the National Eczema Association in the U.S. revealing that almost 60% of eczema patients are interested in participating in a clinical trial for eczema, but fewer than 10% of patients have done so.
The trial of the Facet platform is being remotely run, with Lindus Health responsible for delivering the study, including data capture and management through their proprietary EDC, statistical analysis, and project management.
Neil Parikh, Chief Medical Officer of Thirty Madison, said:
“We are excited to continue to leverage Thirty Madison’s asynchronous telehealth platform to accelerate access to the care continuum - from specialists who support a patient’s clinical journey to a patient’s ability to participate in research studies that advance the treatment landscape. While this study was a small pilot, we are encouraged by the diversity of participants in the study - especially in the area of eczema - where we really need more diverse patient representation."
Meri Beckwith, Co-Founder of Lindus Health, said:
“The Facet platform has the potential to expand treatment access to more eczema patients than ever before. It’s an example of the ground-breaking progress that healthtech companies can make to patient care in the coming years. We’re excited that our innovative clinical trial delivery service can help innovative companies like Thirty Madison bring the latest medical advancements to patients more quickly than the old-fashioned industry standard.”
Lindus Health is an anti-CRO running radically faster and more reliable trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. Lindus Health does this thanks to a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), marrying a world-class clinical operations team with its unique software platform, and access to 30 million Electronic Health Records. Clinical trials are the biggest bottleneck to advances in healthcare and by removing this constraint they aim to improve health for everyone. They handle the end-to-end execution of clinical studies, including design, patient recruitment, clinical data capture, monitoring and project management.
Lindus Health has to date delivered more than 90 trials across the US, UK and Europe to tackle a range of conditions including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia.
The company was named after James Lind, who pioneered the first clinical trial and treatment for scurvy, and co-founded by Michael Young, a former Special Adviser to the UK Prime Minister on Life Sciences, and Meri Beckwith, a former life sciences investor.
The company has raised over $24M from investors including Peter Thiel, CREANDUM, Firstminute Capital, Presight Capital, Seedcamp, Hambro Perks, Amino Collective and Calm/Storm.
Thirty Madison exists to deliver on healthcare's biggest opportunities: access and affordability; patient outcomes; and patient experience. Each of its specialized brands is focused on specific chronic condition areas, and thoughtfully designed to support the unique needs of its community with personalized treatments and care. With empathy at the heart of its innovation, its proprietary care model empowers hundreds of thousands of people with ongoing conditions with the accessible, effective treatments across a lifetime of care. Learn more at ThirtyMadison.com.
Lindus Health and Sooma Medical announce pivotal device clinical trial for treatment of MDD
Lindus Health and Sooma Medical are partnering on the development of a medical device to treat MDD.
